本文已被:浏览 1802次 下载 1次
中文摘要: 目的:实现抗菌药物的合理使用,降低细菌的耐药率。方法:调取胃肠外科2017-2018年8个季度的哌拉西林钠舒巴坦钠的使用量、肠杆菌科细菌对三代头孢的耐药率以及平均住院日等数据。结果:胃肠外科哌拉西林钠他唑巴坦钠的使用量在前三季度与上年同期比下降;但在第四季度与上年同期比升高。肠杆菌科细菌对三代头孢的耐药率保持稳定。平均住院日同比有明显的减少。结论:完善多科协同管理(AMS)模式,制订感染性疾病路径,建立“抗菌药物监测”、“ 微生物监测”和“院内感染监测”的三方合作,同时加大公众宣传教育力度,减少β内酰胺酶抑制剂的预防用药。
中文关键词: 多科协同管理,药物合理应用,β内酰胺酶抑制剂
Abstract:Objective:To realize the rational use of antibacterial drugs and reduce the drug resistance rate of bacteria. Methods:Obtain the usage of Piperacillin Sodium and Sulbactam Sodium for Injection,the enterobacteriaceae bacteria resistant rate of third generations of cephalosporins and the average length of stay in gastroenterology quarterly from 2017 to 2018. Results:We found that the usage of Piperacillin Sodium and Sulbactam Sodium for Injection in the first three quarters year-on-year decline,but it rose in the fourth quarter from a year earlier. The resistance rate of enterobacteriaceae bacteria to the third generation cephalospora remained stable. The average length of hospital stays decreased significantly year-on-year. Conclusions:By improving the cooperation model of AMS,the tripartite cooperation of “antibacterial drug monitoring”,“microbial monitoring” and “nosocomial infection monitoring” should be established. Meanwhile,public publicity and education should be intensified to reduce the prevention of lactamase inhibitors.
keywords: AMS MDT β lactamase inhibitors
文章编号: 中图分类号: 文献标志码:
基金项目:2019年度江苏现代医院管理研究中心立项课题(JSY-3-2019-107) 2019年度江苏现代医院管理研究中心立项课题(JSY-3-2019-107)
引用文本:
张 妍,倪慧萍,华 飞,金晔萍,王玉月,杨立飞,徐 婷,徐 茵*.基于多学科管理的β内酰胺酶抑制剂的管控分析与思考△[J].江苏卫生事业管理,2020,31(5):600-602.
ZHANG Yan,NI Huiping,HUA Fei,JIN Yeping,WANG Yuyue,YANG Liffei,XU Ting,XU Yin*.Analysis and thinking on the control of β lactamase inhibitors based on AMS△[J].Jiangsu Health System Management,2020,31(5):600-602.
张 妍,倪慧萍,华 飞,金晔萍,王玉月,杨立飞,徐 婷,徐 茵*.基于多学科管理的β内酰胺酶抑制剂的管控分析与思考△[J].江苏卫生事业管理,2020,31(5):600-602.
ZHANG Yan,NI Huiping,HUA Fei,JIN Yeping,WANG Yuyue,YANG Liffei,XU Ting,XU Yin*.Analysis and thinking on the control of β lactamase inhibitors based on AMS△[J].Jiangsu Health System Management,2020,31(5):600-602.